NCT02325739 - FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression | Biotech Hunter

Enrollment

172

Participants

Timeline

Start Date

December 29, 2014

Primary Completion Date

May 30, 2019

Study Completion Date

May 30, 2019

Conditions

Hepatocellular Carcinoma (HCC)Solid Malignancies

Interventions

DRUG

FGF401

FGF401 is a FGFR4 inhibitor.

BIOLOGICAL

PDR001

PDR001 is a humanized anti-PD1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2

Trial Locations (27)

10002

Novartis Investigative Site, Taipei

20132

Novartis Investigative Site, Milan

28034

Novartis Investigative Site, Madrid

30625

Novartis Investigative Site, Hanover

31059

Novartis Investigative Site, Toulouse

33604

Novartis Investigative Site, Pessac

34295

Novartis Investigative Site, Montpellier

35062

Novartis Investigative Site, Rennes

41124

Novartis Investigative Site, Modena

45147

Novartis Investigative Site, Essen

59037

Novartis Investigative Site, Lille

69120

Novartis Investigative Site, Heidelberg

70403

Novartis Investigative Site, Tainan City

77030

Uni Of TX MD Anderson Cancer Cntr, Houston

90095

University of California LA Santa Monica Location, Los Angeles

97080

Novartis Investigative Site, Würzburg

168583

Novartis Investigative Site, Singapore

200032

Novartis Investigative Site, Shanghai

02114

Massachusetts General Hospital Oncology Dept, Boston

Unknown

Novartis Investigative Site, Hong Kong

589 8511

Novartis Investigative Site, Ōsaka-sayama

104 0045

Novartis Investigative Site, Chuo Ku

03080

Novartis Investigative Site, Seoul

05505

Novartis Investigative Site, Seoul

06351

Novartis Investigative Site, Seoul

08035

Novartis Investigative Site, Barcelona

08036

Novartis Investigative Site, Barcelona